Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?

Area of Science:

• Cardiovascular Biology
• Metabolic Regulation
• Cardiac Regeneration

Background:

• Neonatal cardiomyocytes undergo metabolic reprogramming, shifting nutrient utilization (glucose, fatty acids, amino acids), which coincides with cell cycle arrest.
• Myocardial infarction in adult hearts triggers metabolic reprogramming, but it is insufficient to drive cardiomyocyte proliferation and replace lost cells.
• Metabolic reprogramming is influenced by factors like oxygen levels, substrate availability, hemodynamic stress, and hormones.

Purpose of the Study:

• To review the features, triggers, and molecular networks of metabolic reprogramming in cardiomyocytes.
• To discuss the role of metabolic reprogramming as a critical determinant of cardiomyocyte proliferation and cardiac regeneration.
• To explore the potential of metabolic manipulation as a therapeutic strategy for heart disease.

Main Methods:

• Review of existing literature on cardiomyocyte metabolism and proliferation.
• Analysis of studies investigating the effects of metabolic enzyme alterations on cardiomyocyte cell cycle activity.
• Discussion of proposed mechanisms linking metabolic reprogramming to cell cycle regulation.

Main Results:

• Altering specific metabolic enzymes (PKM2, LDHA, PDK4, SDH, CPT1b, HMGCS2) can partially reverse metabolic reprogramming and promote adult cardiomyocyte proliferation.
• Metabolic reprogramming is a key feature of both neonatal cardiomyocyte cell cycle arrest and the adult heart's limited regenerative capacity post-injury.
• Potential mechanisms involve metabolic intermediates regulating biosynthetic pathways and epigenetic modifications.

Conclusions:

• Metabolic reprogramming is a critical factor influencing cardiomyocyte proliferation and cardiac regeneration.
• Targeting metabolic pathways and enzymes presents a promising, yet unoptimized, approach for stimulating cardiac repair.
• Further research is needed to define novel molecular targets and optimize metabolic interventions for treating myocardial infarction and other heart conditions.